274 related articles for article (PubMed ID: 34157799)
21. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
Hajem S; Ederhy S; Champiat S; Troalen F; Nolin-Lapalme A; Berhoune M; Cauquil C; Martin-Romano P; Baldini C; Laparra A; Vuagnat P; Hollebecque A; Mateus C; Besse B; Naltet C; Robert C; Marabelle A; Massard C; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 157():383-390. PubMed ID: 34571335
[TBL] [Abstract][Full Text] [Related]
22. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
23. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
24. Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor-induced myocarditis: A case series and review.
Ke G; Chen P; Luo J; Huang J; Shang Y; Huang Y; Fu N; Peng H; Li Y; Wang B; Guan W; Peng Y; Yu X; Xiao J
Clin Cardiol; 2023 Dec; 46(12):1481-1487. PubMed ID: 37698123
[TBL] [Abstract][Full Text] [Related]
25. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
Chen K; Sun B
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):927-940. PubMed ID: 33203196
[TBL] [Abstract][Full Text] [Related]
26. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
27. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
Kurino T; Matsuda R; Terui A; Suzuki H; Kokubo T; Uehara T; Arano Y; Hisaka A; Hatakeyama H
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041818
[TBL] [Abstract][Full Text] [Related]
28. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
29. Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression.
Martinez Valenzuela L; Gómez-Preciado F; Guiteras J; Antón Pampols P; Gomà M; Fulladosa X; Cruzado JM; Torras J; Draibe J
J Transl Med; 2024 May; 22(1):421. PubMed ID: 38702780
[TBL] [Abstract][Full Text] [Related]
30. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
31. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
32. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
33. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.
Lucas JA; Menke J; Rabacal WA; Schoen FJ; Sharpe AH; Kelley VR
J Immunol; 2008 Aug; 181(4):2513-21. PubMed ID: 18684942
[TBL] [Abstract][Full Text] [Related]
34. Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.
Sobol I; Chen CL; Mahmood SS; Borczuk AC
Arch Pathol Lab Med; 2020 Nov; 144(11):1392-1396. PubMed ID: 32150459
[TBL] [Abstract][Full Text] [Related]
35. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
Cozma A; Sporis ND; Lazar AL; Buruiana A; Ganea AM; Malinescu TV; Berechet BM; Fodor A; Sitar-Taut AV; Vlad VC; Negrean V; Orasan OH
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142866
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis.
Zhao Y; Hao C; Li M; Qu Y; Guo Y; Deng X; Si H; Yao W
Biomed Pharmacother; 2022 Apr; 148():112768. PubMed ID: 35247717
[TBL] [Abstract][Full Text] [Related]
37. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
38. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
39. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
